Please assess the completion status of the following clinical trial:

Trial Title: Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants who had inadequate response to \>= 2 non-steroidal anti-inflammatories (NSAIDs)~* Participants who had arthritis or enthesitis or dactylitis plus: met spondyloarthritis clinical criteria~* Negative purified protein derivative (PPD) test and Chest X-Ray performed at Baseline Visit were Negative~* Ability to administer subcutaneous injections~* General good health~Exclusion Criteria:~* Prior anti-tumor necrosis factor (TNF) therapy~* Psoriasis or Psoriatic Arthritis~* Fulfillment of modified New York criteria for Ankylosing Spondylitis~* Recent infection requiring treatment~* Significant medical events or conditions that had put patients at risk for participation~* Female participants who were pregnant or breast-feeding or considering becoming pregnant during the study~* History of cancer, except successfully treated skin cancer~* Recent history of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-blind (DB) Adalimumab (Type: EXPERIMENTAL): Adalimumab 40 mg subcutaneous (SC) injection every other week (eow) up to Week 12 in double-blind period.
- Double-blind Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous (SC) injection every other week (eow) up to Week 12 in the double-blind period.
- Double-blind Adalimumab / Open-label Adalimumab (Type: EXPERIMENTAL): Adalimumab 40 mg SC injection eow up to Week 12 in double-blind period and from Week 12 to Week 156 in open-label period.
- Double-blind Placebo / Open-label Adalimumab (Type: PLACEBO_COMPARATOR): Placebo SC injection every other week (eow) up to Week 12 in the double-blind period; adalimumab 40 mg subcutaneous injection eow from Week 12 to Week 156 in the open-label period.

Based on this trial design, predict the completion outcome and termination type (if applicable).